NCT07288073 2026-02-13TIL Therapy in cSCC and MCCDana-Farber Cancer InstitutePhase 2 Recruiting14 enrolled
NCT04551885 2023-09-21FT516 in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate TherapeuticsPhase 1 Terminated12 enrolled
NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled
NCT04596033 2022-07-15TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell TherapyGenocea Biosciences, Inc.Phase 1 Terminated49 enrolled